The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture
- 22 October 2012
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 33 (1), 127-136
- https://doi.org/10.1111/liv.12011
Abstract
Background Chemoresistance and advanced tumour stage at time of diagnosis are the major reasons for poor treatment results in hepatoblastoma (HB) and paediatric hepatocellular carcinoma (HCC). Positive results with transplantation of liver and bone marrow revealed the impact of the immune system on the treatment of liver malignancies. Aim Cytotoxic-immune-cells-like natural killer (NK) and T cells are major player in the defence against developing tumours. This study aimed to specifically analyse the ability of ex-vivo expanded γδ T cells to recognise and lyse HB and HCC cell lines in coculture assays. Methods Cell viability after treatment with γδ T cells was evaluated with two HB (HUH6 and HepT1) and one HCC cell line (HC-AFW1) using a MTT-based cytotoxicity assay. The binding of T cells to target cells was monitored using immunofluorescence microscopy. Results Incubation of hepatic tumour cell lines with γδ T cells led to a significant decrease in tumour cell viability. This was enhanced by zoledronic acid and histone deacetylase inhibitors. MT110, an EpCAM/CD3-bispecific BiTE antibody could bluntly enhance tumour cell lysis close to completion. γδ T cells efficiently interacted with HB and HCC cells in a spheroid culture model. Conclusion Bispecific antibodies such as MT110 might be used to intensify the antitumoural effect of γδ T cells in context of adoptive immune cell transfer. Optimised immunotherapeutic strategies might therefore improve the outcome of high risk hepatoblastoma and hepatocellular carcinoma.Keywords
Funding Information
- Faculty of Medicine
This publication has 44 references indexed in Scilit:
- Characterisation of the Cell Line HC-AFW1 Derived from a Pediatric Hepatocellular CarcinomaPLOS ONE, 2012
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumoursBritish Journal of Cancer, 2011
- γδ T-cell immunotherapy for lung cancerSurgery Today, 2011
- γδT Cells Cross-Link Innate and Adaptive Immunity inMycobacterium tuberculosisInfectionClinical and Developmental Immunology, 2011
- Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T CellsPLOS ONE, 2010
- Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical ProstatectomyUrologia Internationalis, 2010
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerAnnals Of Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Isopentenyl Pyrophosphate–Activated CD56+ γδ T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell CarcinomaClinical Cancer Research, 2008
- Liver transplantation for hepatocellular carcinoma in childrenPediatric Transplantation, 2008